Anemia at the Initiation of Tuberculosis Therapy Is Associated with Delayed Sputum Conversion among Pulmonary Tuberculosis Patients in Dar-es-Salaam, Tanzania by Nagu, Tumaini J. et al.
 
Anemia at the Initiation of Tuberculosis Therapy Is Associated with
Delayed Sputum Conversion among Pulmonary Tuberculosis
Patients in Dar-es-Salaam, Tanzania
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Nagu, Tumaini J., Donna Spiegelman, Ellen Hertzmark, Said
Aboud, Julie Makani, Mecky I. Matee, Wafaie Fawzi, and
Ferdinand Mugusi. 2014. “Anemia at the Initiation of Tuberculosis
Therapy Is Associated with Delayed Sputum Conversion among
Pulmonary Tuberculosis Patients in Dar-es-Salaam, Tanzania.”
PLoS ONE 9 (3): e91229. doi:10.1371/journal.pone.0091229.
http://dx.doi.org/10.1371/journal.pone.0091229.
Published Version doi:10.1371/journal.pone.0091229
Accessed February 19, 2015 3:37:48 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064366
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAAnemia at the Initiation of Tuberculosis Therapy Is
Associated with Delayed Sputum Conversion among
Pulmonary Tuberculosis Patients in Dar-es-Salaam,
Tanzania
Tumaini J. Nagu
1,2*, Donna Spiegelman
3,4, Ellen Hertzmark
3, Said Aboud
5, Julie Makani
6,
Mecky I. Matee
5, Wafaie Fawzi
7, Ferdinand Mugusi
1
1Department of Internal Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Dar- es- Salaam, Tanzania, 2Department of Laboratory Medicine,
Karolinska Institutet (KI), Stockholm, Sweden, 3Department of Epidemiology, Harvard School of Public Health (HSPH), Boston, Massachusetts, United States of America,
4Department of Biostatistics, Harvard School of Public Health (HSPH), Boston, Massachusetts, United States of America, 5Department of Microbiology and Immunology,
Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania, 6Department of Hematology, Muhimbili University of Health and Allied Sciences
(MUHAS), Dar- es- Salaam, Tanzania, 7Department of Global Health and Population, Harvard School of Public Health (HSPH), Boston, Massachusetts, United States of
America
Abstract
Background: Pulmonary tuberculosis and anemia are both prevalent in Tanzania. There is limited and inconsistent literature
on the association between anemia and sputum conversion following tuberculosis treatment.
Methods: Newly diagnosed sputum smear positive pulmonary tuberculosis patients aged $15 years initiating on standard
anti tuberculosis therapy were recruited from 14 of 54 tuberculosis clinics in Dar es Salaam. Patients were receiving
medication according to the recommended short course Directly Observed Therapy (DOT) strategy and were followed up
prospectively until completion of treatment (six months). Patients were evaluated before initiation of TB treatment by
performing the following; clinical history, physical examination, complete blood counts, serum biochemistry and sputum
microscopy. Sputum smears were re-examined at two months of anti-tuberculosis therapy for presence of acid fast bacilli.
Anemia was defined as hemoglobin ,13 g/dl (males) or ,12 g/dl (females). Log-binomial regression was used to assess the
association between anemia and sputum conversion at two months.
Results: Of the 1245 patients included in the study, 86% were anemic and 7% were sputum smear positive at two months of
anti-tuberculosis therapy. Anemic patients were three times more likely to have sputum positive smear as compared to non-
anemic patients at two months (RR=3.05; 95% CI 1.11–8.40) p=0.03. The risk for sputum positive smear results increased
with severity of anemia (P for trend ,0.01).
Conclusion: Baseline anemia is associated with increased risk for persistent positive sputum smears at two months of
tuberculosis treatment. Future studies should evaluate the mechanisms for TB-associated anemia as well as the role of
intervention for anemia among TB patients.
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Introduction
Tuberculosis (TB) is the world’s second most common cause of
death from infectious diseases [1,2]. In 2011, a total of 8.7 million
new active TB cases and 1.4 million TB related deaths were
estimated worldwide; 70% of these deaths were among HIV
uninfected people [2]. It is evident there is need to strengthen
strategies for infection control, identification and management of
TB patients at increased risk for death in addition to identifying
effective chemotherapy, in order to reduce TB related morbidity
and mortality.
Smear positivity is the most important predictor of TB
infectiousness [3,4]. When smear positive TB patients initiate
TB therapy containing rifampicin and isoniazid, there is a rapid
multifold reduction in bacillary load expelled in sputum which
minimizes the risk for transmission [5]. About 90% of patients are
likely to become smear and/or culture negative (smear and/or
culture conversion) after two to three months of TB chemotherapy
[6–9]. However, approximately 10% of TB patients are still
culture positive 60 days following initiation of anti TB therapy [6],
implying a potential for persistent infectiousness. Furthermore,
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e91229longer smear conversion times have been associated with
subsequent poor TB treatment outcomes and relapse within two
years of follow up [10,11]. Some risk factors have been identified
for delayed time to smear conversion. These include cavitatory
lesions, high initial sputum smear acid fast bacillary (AFB) counts,
multi drug resistant TB, old age, diabetes and duration of
symptoms before treatment [10,12,13].
Anemia is estimated to occur in 1–8% of the world’s population
[14]. It is the third cause of global years lived with disability (YLD),
responsible for more than 600 YLD per 100,000 people [14], and
shows regional variation in incidence and prevalence [14,15]. In
eastern sub-Saharan Africa, anemia is the leading cause of years
lived with disability (YLDs) [14]. The prevalence of anemia among
TB patients ranges between 30–94% [16–20]. It has been shown
that anemia is more likely to occur among TB patients compared
to healthy controls [21]. More importantly, anemia is associated
with more severe forms of TB [22] and poorer TB outcomes,
including deaths [17,19,23]. There is scanty and inconsistent
literature on the relationship between anemia and sputum smear
conversion. One study showed no association between anemia and
TB culture positivity at one month of TB therapy [17], while
another found a higher mean hemoglobin following sputum smear
conversion at two months of TB therapy compared to baseline
hemoglobin [22].
We conducted a prospective study to examine the effect of
baseline anemia on sputum smear conversion at two months of
anti-tuberculosis chemotherapy.
Materials and Methods
Ethics statement
The study was cleared by Muhimbili University of Health and
Allied Sciences (MUHAS) ethical review board. Permission to
conduct the study was obtained from the Kinondoni, Temeke and
Ilala Municipal directors for health. Prior informed written
consent was sought from all participating patients. Patients aged
15–17 years gave an assent to participate in the study, and their
parents or guardians signed a written consent. All patients were
managed according to the national TB management protocol.
Setting and study design
This prospective study was conducted in Dar es Salaam,
Tanzania, a commercial city with about 4 million inhabitants and
a population density of 3133 per square kilometer, compared to
the Tanzanian national average of 51 inhabitants per square
kilometer [24]. Dar es Salaam had the highest TB notification
rate, with 22% of 61,838 TB cases reported in Tanzania in 2011
[25]. This study was conducted in between October 28
th 2010 and
December 20
th 2011 in the 14 largest TB clinics (of the total 54 TB
diagnostic and treatment clinics in Dar es Salaam), based on the
National Tuberculosis data. The list resulted in 4 or 5 clinics from
each of the three municipalities in Dar es Salaam.
Patients
Study participants were consenting pulmonary tuberculosis
(PTB) patients (defined as having at least two positive results of
smear for acid fast bacilli (AFB) on microscopy), aged 15 years and
above. Patients were treated according to the national guidelines
for the management of TB [26], which stipulates daily direct
observed therapy (DOT) throughout the six months of anti-TB
drug administration. In Tanzania, patients have the choice of
taking medication at Health facility (facility DOT) or at their home
in the presence of a community treatment supporter (community
DOT). For community DOT, a weekly supply of TB drugs is
provided, while ensuring adherence during refill using patients’
treatment cards. Therapy consisted of a two month intensive phase
of daily rifampicin, isoniazid, pyrazinamide and ethambutol. At
the end of the intensive phase, PTB patients whose follow up
smears were negative for AFB on microscopy continued with daily
rifampicin and isoniazid for an additional four months. Patients
whose two months follow up sputum smears were positive for AFB
on microscopy had an extended intensive phase for one more
month. We excluded all patients who had used anti TB drugs
within the past two years or who stated that they did not intend to
stay in Dar es Salaam until completion of their treatment.
Study procedures
Following consent, clinicians conducted interviews, performed
physical examinations, filled the case report forms (CRF) and
obtain sputum and blood samples. Patients were reviewed at two
and five and six months by attending clinicians who also recorded
the sputum smear results and patient outcomes at the end of
treatment as stipulated by the National TB and Leprosy Control
Programme [26].
Laboratory investigations
Sputum smears were prepared using Ziehl–Neelsen (ZN) stain
and were examined for acid fast bacilli (AFB) at: baseline, and at
two and five months of TB treatment. Results were reported on
the laboratory request forms and documented on the clinic TB
registers. Drug susceptibility testing (DST) was performed at the
central reference Tuberculosis Laboratory located at Muhimbili
National Hospital. We initially performed DST using the
BACTEC Mycobacteria Growth Indicator Tube (MGIT) –
(Beckton-Dickinson) technique according to manufacturer’s in-
structions. Due to limited resources, we had to change to
conventional, egg-based Lowenstein Jensen (LJ) media. Each
sample was then cultured in Lowenstein Jensen media at 37uC for
up to 8 weeks. Plates were examined weekly for growth. Colonies
were identified according to criteria based on the speed of growth
and macroscopic features e.g. roughness and pigment production
and ZN smear microscopy. DST was performed by the proportion
method. Complete blood count (hemoglobin; white cell count,
neutrophils, lymphocytes, monocytes, eosinophil and basophil;
and platelets) was performed using the ACT5 DIFF hematology
analyser (Beckman Coulter, Miami, Florida). Clinical chemistry:
Alanine aminotransferase, (ALT), bilirubin, serum creatinine, urea
and albumin were performed using Cobas integra 400 plus
Chemistry Analyzer (Roche, Rotkreuz, Switzerland). HIV infec-
tion was determined according to the National HIV screening
algorithm. The algorithm requires serial testing using Determi-
ne
TM HIV-1/2 (Inverness Medical Japan Co. Ltd, Japan) then
Uni-Gold
TM HIV-1/2 (Trinity Biotech, Wicklow, Ireland).
Enzyme Linked Immunosorbent Assay (ELISA) method was used
as a tie breaker in discordant rapid test results.
Quality assurance
Quality assurance was accomplished by assessing the quality
and adequacy of specimens and by monitoring microscopy and
culture procedures according to the established laboratory
operating procedures. Patients were requested to provide addi-
tional specimens in case of submitting either inadequate amounts
or salivary samples. For smear microscopy, positive and negative
control slides were included with each batch of new reagents in a
blind manner. Random sputum specimens were reviewed at
CTRL as quality assurance measure. Additional quality measures
for culture included monitoring of quality of water, decontamina-
tion, digestion and concentration procedures, inspissations and
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of culture media. A standard laboratory strain M. tuberculosis
H37Rv was used as a positive control.
Data management and statistical analysis
Information from CRFs was double entered by trained data
clerks using Epi6 statistical software. Statistical analysis was
conducted using SAS version 9.3 (SAS Institute, Cary, NC)
statistical software. We used proportions to describe the basic
characteristics of the study population at the time of enrolment.
Log-binomial regression was used to assess the association of
baseline anemia with delayed sputum smear conversion [27,28].
When log-binomial models did not converge, the Poisson
approximation was used. Univariate and multivariate analyses
were performed. Variables with p#0.2 in univariate analysis were
included [29] in the multivariate model, in addition to HIV
infection and body mass index (BMI).
The outcome measure for this study was delayed sputum smear
conversion, defined as sputum smear positive for AFB at two
months of antiTB therapy. The primary exposure of interest was
anemia at baseline, defined per World Health Organization
(WHO) guidelines as hemoglobin ,13 g/dl (males) or hemoglobin
,12 g/dl (female) [30]. Anemia was further categorized according
to severity with the following hemoglobin cut off points: mild
anemia; 11.00 – ,13 g/dl (male) and 11.00 – ,12 g/dl (female);
moderate anemia 8.00 – ,11 (both sexes); severe anemia
hemoglobin less than 8 g/dl for both sexes [30].
The primary multivariate analysis for delayed sputum smear
conversion was performed with anemia as a binary variable (Yes
or No). In secondary analysis, we used the anemia severity variable
(no anemia, mild, moderate, severe). Both models adjusted for the
same covariates. In the multivariate model, we adjusted for
potential confounding effects of age (15–29 years, 30–50 years,
.50 years), sex (male/female), HIV status (positive/negative),
cigarette smoking (never, past or current) ,alcohol consumption
(never, past or current), substance abuse (never, past or current),
body mass index (BMI) categories (,18.5 kg/m
2,18.5–25 kg/m
2,
.25 kg/m
2), duration of illness(,4 weeks vs. $4 weeks or
continuous variable with spline term), lymphocyte count
(,1.0610
6cell/mlv s$1.0610
6cells/ml) platelet counts
(,150,000cells/ml, 150,000–400,000 cells/mlo r.400,000 cells/
ml) and resistance to rifampicin and/or isoniazid (yes/no). In the
multivariate models missing indicators were used for covariates
with large numbers of missing values. The relation between
hemoglobin concentration and the risk of delayed sputum
conversion was examined for nonlinearity using restricted cubic
splines [31–32], adjusted for the covariates as described for our
multivariate model. We also modeled our outcomes omitting
platelet count and HIV status, which could mediate the effect of
anemia on delayed sputum conversion. P,0.05 was considered
significant.
Results
During the study period October 28
th 2010 and December 20
th
2011, a total of 1805 sputum smear positive patients were enrolled
and studied. Among these, 357 (19.8%) patients were missing
sputum smear results at two months and a further 203 (11.2%)
patients were missing baseline hemoglobin. We therefore included
1245 patients in this study with baseline hemoglobin and two
months sputum smear results available.
Patients who were excluded were similar to the included
patients in: demographic characteristics (age, sex, marital and
education status); their economic status (monthly income and
expenditure on food); cigarette smoking and alcohol status; disease
severity (BMI and duration of symptoms); proportion with HIV
infection and proportion with rifampicin and/or isoniazid
resistance. Excluded patients had significantly lower lymphocyte
counts (median 1.4610
6 vs. 1.5610
6 cells/ml) p=0.05 and were
more likely to have a history of current (3.2 vs. 1.9) or past (7.29 vs.
2.9) substance abuse (p=,0.0001).
The median age (IQR) of the participants was 32 (25–40) years.
As shown in Table 1, most participants (67%) were males. The
median monthly income and daily expenditure on food for the
study participants were 100 USD and 3 USD respectively. About a
third, 359 (30%) of the study participants had HIV infection, 3
(0.46%) had rifampicin resistance, of whom one had multi drug
resistant (MDR) TB, and 20 patients (3.05%), had resistance to
either rifampicin or isoniazid.
Anemia was present in 1067 (86%) patients of the study
population, of the anemic patients two thirds 697 (65%) had
moderate to severe anemia. Delayed sputum smear conversion
occurred in 82 (7%) patients.
Table 2 shows the association between anemia at the time of
enrollment and delayed sputum smear conversion at two months
of TB therapy. In the adjusted model, patients with anemia at the
time of enrolment were three times more likely to have delayed
sputum smear conversion than patients without anemia,
(RR=3.05; 95% CI 1.11–8.40; p=0.03) (Table 2). When anemia
severity was modeled in a separate multivariable analysis, the
likelihood of delayed sputum smear conversion increased with
severity of anemia (trend test P,0.01). Patients with mild anemia
had a nearly 3-fold increased risk of delayed sputum smear
conversion (RR=2.72; 95%CI 0.94–7.85) compared to those
without anemia, whereas patients with severe anemia were five
times as likely to have delayed sputum smear conversion as those
without anemia (RR=5.08; 95% CI 1.65–15.62) p,0.01.
Examination of the relation of baseline hemoglobin to delayed
sputum conversion showed a linear relation, with and adjusted risk
ratio of 0.84 (95% CI 0.76–0.94; p,0.01) per gram of hemoglobin
per deciliter. No evidence of nonlinearity was found. Modification
of the basic models, either by using continuous duration of illness
with the spline variable or by excluding platelet count and HIV
status, did not materially change the results. The relative risks for
anemia with or without platelet count and HIV status ranged from
2.86 to 3.12 respectively.
Other potential predictors of delayed sputum smear conversion
that were investigated in this study are shown in Table 3. Older
patients aged 30–50 years had a higher risk for delayed sputum
smear conversion (RR=1.93; 95% CI 1.13–3.31) compared to
patients aged 15 – ,30 years. Current smokers were about twice
as likely to have delayed sputum smear conversion (RR 2.13;
95%CI 1.02–4.45) as never smokers (p=0.04). Resistance to either
rifampicin or isoniazid was significantly associated with delayed
sputum smear conversion (RR=2.74; 95% CI 1.26–5.97)
p=0.01. Patients with low lymphocyte count (,1.0610
6 cells/
ml) were significantly more likely to delay sputum smear conversion
(RR=1.77; 95% CI 1.16–2.70) compared to those with lympho-
cyte count of 1.0610
6 cells/ml or above (p=0.008). We found no
evidence for increased risk for delayed sputum smear conversion
among those who had quit smoking. There was no association
between delayed sputum smear conversion and BMI or HIV
infection. Alcohol use, substance abuse, and duration of illness
were significantly associated with delayed sputum smear conver-
sion at univariate but not multivariate analysis (Table 3). Sex,
monthly income, daily expenditure on food, marital and education
status were not significantly associated with delayed sputum smear
conversion (Table 3).
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delayed sputum smear conversion by age, sex, mean corpuscular
volume (MCV), cigarette smoking, alcohol use, substance abuse,
duration of illness, platelets, or BMI (data not shown).
Discussion
Infection control in TB therapy entails early diagnosis and
effective treatment of TB patients. In this regard, sputum smear
microscopy at two months of anti TB therapy is key in the
assessment of TB therapy outcome. Our current study is one of the
few studies that have examined the association of anemia with
sputum smear conversion after two months of treatment. In this
study, we report two important findings. First, anemia is
independently associated with delayed sputum smear conversion
at two months of anti TB therapy. Secondly, the relationship
between anemia and delayed sputum conversion displays a dose-
response effect.
Our findings contradict an earlier study done in similar setting
[17] which did not find any association between anemia and
sputum culture conversion at one month of anti TB therapy [17].
There are three possible reasons for this difference. First, the
smaller sample size in the prior study compared to ours would
limit their power to detect small difference if any. Second, the
study involved patients with less severe forms of anemia, (all
participants had hemoglobin .7 g/dl) [17]. Indeed, as shown in
our study, those with milder forms of anemia had a smaller risk for
delayed sputum conversion, suggesting the need for a bigger
sample size to have adequate statistical power to detect the smaller
effect. Third, the discrepancy could be accounted for by difference
in methods of outcome assessment: the former study used culture
conversion, which is a known more stringent method compared to
sputum smear microscopy adopted by our study. Morris et al [22],
showed that sputum non conversion among TB patients was
correlated with persistency of anemia during treatment of TB.
Further, these authors reported lower mean hemoglobin among
patients with positive sputum smear compared to those with
negative sputum smear at three months.
Mechanisms that explain the association between delayed
sputum conversion and baseline anemia are yet to be established.
Tuberculosis causes anemia but why some patients do not become
anemic is unclear. In previous reports, malnourished TB patients
had lower mean levels of hemoglobin and zinc, compared to
healthy controls, malnourished controls and well-nourished TB
patients [21]. In addition, TB patients with zinc deficiency had
impaired T-cell immunity [33]. In our study, underweight (BMI
,18.5 kg/m
2) observed in more than half of the study population,
Table 1. Baseline characteristics of patients at the time of
initiation of Tuberculosis (TB) therapy (N=1245).
Variable Missing No (%) No %
Male sex 0 831 67
Age (years) 32 (2.57)
15 - ,30 485 40
30–50 618 51
.50 110 9
Marital Status 16 (1.29)
Never married 580 47
Cohabiting/married 531 43
Divorced/widowed 118 10
Education status 20 (1.61)
No formal education 77 6
Primary school 881 72
Secondary and above 267 22
Monthly income (USD) 275 (22.09)
,100 418 43
$100 552 57
Daily family expenditure on food (USD)200 (16.06)
,3 432 41
$3 613 59
Smoking 13 (1.04)
Never 912 74
Quit 263 21
Current 57 5
Alcohol 20 (1.61)
Never 779 63
Quit 352 29
Current 94 8
Substance abuse 35 (2.81)
Never 1154 95
Quit 34 3
Current 22 2
BMI categories kg/m
2 126 (9.96)
,18.5 575 51
18.5 - ,25 501 45
$25 45 4
Duration of illness (weeks) 103 (8.2)
,4 266 23
$4 876 77
HIV positive 58 (4.66) 359 30
Resistance to anti TB drugs
Isoniazid (H) resistance 590 (47.45) 18 2.75
Rifampicin (R) resistance 590 (47.45) 3 0.46
R or H resistance 590 (47.45) 20 3.05
Lymphocyte count (610
6 cells/ml) 2 (0.2)
,1.0 302 24
$1.0 941 76
MCV 3 (0.24)
,80 615 50
Table 1. Cont.
Variable Missing No (%) No %
$80 627 50
Platelets (cells/ml) 4 (0.3)
,150,000 123 10
150,000–400,000 658 53
.400,000 460 37
Serum creatinine 221 (17.75)
#110 961 94
.110 63 6
doi:10.1371/journal.pone.0091229.t001
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have mediated the complex immune interaction between sputum
conversion, anemia, and malnutrition, which can’t be determined
by the current study. Another possible mechanism for the
relationship between anemia and delayed smear sputum conver-
sion could be iron deficiency. Low ferritin levels have been
reported to predict treatment failure at one month of TB therapy
[34]. Iron deficiency among patients impairs host T-cell immunity
mediated through interference with effector cell activity [35,36].
Evidence on the association between cigarette smoking and
sputum conversion is limited and inconclusive [37]. In line with
previous studies, we found an increased risk of delayed sputum
conversion among current smokers [12], but not among those who
had quit smoking. Visser et al [38] did not find a significant
association between baseline smoking and sputum culture
conversion. This inconsistency may have been caused by different
definitions of smoking used in the studies: ‘ever vs never smokers’
(Visser) ‘current vs past vs never smokers’ (our study). Our study
found no effect on sputum conversion among past smokers. This
finding, however, should be confirmed by other independent
studies. Smoking in known to promote mycobacterial adherence to
airway epithelial cells by affecting virulence changes in the
respiratory tree that favor TB infection and delays clearance of
the infection [39].
Older age has been associated with poorer TB outcomes
including sputum conversion and death [12,40]. In our study, we
observed a trend of increasing age related to higher risk of sputum
conversion. Similar to previous studies, we found that resistance to
isoniazid and rifampicin predicted delayed sputum conversion
[6,7]. Patients with mycobacteria TB resistance to isoniazid and
rifampicin do not respond well to first-line anti-TB drugs,
warranting switch to second-line anti TB. This finding emphasizes
the need for drug susceptibility testing (DST) among newly
diagnosed TB patients using available GenExpert machines. We
found a significant association between lymphopenia and delayed
sputum conversion. Both lymphocytosis and lymphopenia have
been found to occur among TB patients [22]. Low lymphocyte
count has been shown to occur among patients with more severe
forms of TB [41] which may in part explain delayed sputum
conversion [12]. In agreement with previous studies during the
antiretroviral therapy (ART) era, we did not find any significant
association between delayed sputum conversion and HIV infection
[42,43]. The lack of association between HIV and delayed sputum
conversion is probably indirect evidence for the beneficial effects of
the scale up of ART in Dar es Salaam, as well as improved TB/
HIV collaborating services demonstrated in settings similar to that
of the study area [44]. The outcome of TB patients has been found
to be similar regardless of HIV status as long as HIV patients are
kept on ART [43]. We did not collect information on ART use for
our study, however, in our study setting, all newly identified HIV
co-infected TB patients are initiated on ART in the same clinics
[45].
Our study had some limitations. First, we excluded 31% of
patients for whom sputum smear results at two months was not
available or did not have baseline hemoglobin results. In the
comparative analysis we found that the excluded patients had, on
average, lower lymphocyte counts and were more likely to have
had a current or past history of substance abuse. The literature, as
well as our current findings suggest that delayed sputum
conversion is associated with low lymphocyte count and substance
use [12,41,43]. It is likely in this scenario that the association
between sputum conversion and anemia could be stronger.
Second, because we did not perform mycobacteria cultures at
two months, there could have been a possibility of reporting non-
viable mycobacteria [10]. However, in most cases, smear
conversion precedes culture conversion, and almost all smear
positive cases are culture positive at two months [6–8]. Third,
adherence to anti TB is an important factor for sputum conversion
and cure and could have introduced bias in our study. In the study
setting, anti-TB therapy is administered as daily direct observed
therapy (DOT) throughout the duration of treatment by either a
health care worker at health facility (facility DOT) or a community
treatment supporter (community DOT) according to patient’s
preference [26]. Adherence to anti-TB in Tanzania has been
shown to be as high as 99% when urine samples were tested for
metabolites of the drugs among TB patients [46]. Finally,
Pregnancy is known to cause anemia, in this study we did not
exclude or identify pregnant women. It is worth noting that
women composed one- third of the study population.
Despite the limitations, our study has some important contri-
bution to science and policy with regards to patient management.
This work is one of the very few current attempts to show the
importance of anemia on TB patient outcomes in the era of HIV.
It is large and was conducted in a TB programmatic setting
Table 2. The association between delayed sputum conversion and anemia among Tuberculosis patients (N=1245)*.
Predictor Event/# at risk Unadjusted model Adjusted model
RR (95% CI) P RR (95% CI) P
Anemia
No anemia 4/178 1 1
Anemia 78/1067 3.25 (1.21–8.77) 0.02 3.05 (1.11–8.40) 0.03
Anemia severity
No 4/178 1 1
Mild 24/370 2.89 (1.02–8.19) 2.72 (0.94–7.85)
Moderate 38/542 3.12 (1.13–8.62) 3. 02 (1.07–8.55)
Severe 16/155 4.59 (1.57–13.45) ,0.01 5.08 (1.65–15.62) ,0.01**
Hemoglobin (g/dl) 82/1245 0.87 (0.80–0.95) ,0.01 0.84 (0.76–0.94) ,0.01
*Two separate models for (anemia and anemia severity) were each adjusted for: age, sex, HIV status, smoking, alcohol, drug abuse, body mass index (BMI), duration of
illness, lymphocytes, platelets count and resistance to rifampicin and/or Isoniazid.
**Trend test p-value.
doi:10.1371/journal.pone.0091229.t002
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policies that may improve TB patients’ outcomes. Given the large
burden of anemia among TB patients, representation of the
categories of severity of anemia in our study population provides
room for priority setting. The dose-response effect of anemia that
was shown in this study underscores the rigorousness of the
association between anemia and sputum smear conversion. If our
findings are taken into consideration, and lead to treatment of
Table 3. Predictors of delayed sputum smear conversion among Tuberculosis patients (n=1245)*.
Univariate analysis Multivariate analysis
Predictor RR (95% CI) P RR (95% CI) P
Anemia
No 1 1
Yes 3.25 (1.21–8.77) 0.02 3.05 (1.11–8.40) 0.03
Age (Years)
15 – ,30 1 1
30–50 2.18 (1.31–3.65) 1.93 (1.13–3.31)
.50 1.86 (0.83–4.13) ,0.01 1.88 (0.85–4.14) 0.03
Sex
Female 1 1
Male 1.96 (1.13–3.21) 0.02 1.36 (0.76–2.43) 0.30
Smoking status
Never 1 1
Quit 1.95 (1.20–3.12) 1.35 (0.76–2.42)
Current 4.33 (2.43–7.12) ,.0001 2.13 (1.02–4.45) 0.04
Alcohol
Never 1 1
Quit 1.55 (0.90–2.47) 1.05 (0.60–1.82)
Current 2.79 (1.50–4.84) 0.001 1.21 (0.59–2.50) 0.68
Substance abuse
Never 1 1
Quit 1.92 (0.74–4.94) 1.23 (0.53–2.85)
Current 3.70 (1.66–8.25) ,0.001 2.12 (0.95–4.73) 0.07
BMI categories (Kg/m
3)
,18.50 0.87 (0.56–1.35) 0.72 (0.48–1.10)
18.5–24.99 1 0.91 1 0.63
$25.00 0.03 (0.04–2.14) 0.31(0.04–2.23)
Duration of illness (weeks)
$41 1
,4 2.24 (1.25–3.99) ,0.01 1.48 (0.80–2.72) 0.21
Rifampicin/Isoniazid Resistance
No 1 1
Yes 2.33 (0.80–6.75) 0.12 2.74 (1.26–5.97) 0.01
HIV infection
No 1 1
Yes 0.85 (0.52–1.38) 0.52 0.77 (0.46–1.29) 0.32
Lymphocytes 610
6 (cells/ml)
$1.0 1 1
,1.0 1.80 (1.17–2.77) ,0.01 1.77 (1.16–2.70) ,0.01
Platelets (cells/ml)
,150,000 0.88 (0.37–2.02) 0.83 (0.36–1.91)
150,000–400,000 1 1
.400,000 1.52 (0.98–2.34) 0.12 1.48 (0.98–2.25) 0.17
*Additionally controlled for marital status, education status, monthly income, daily expenditure on food and serum creatinine, none of which were significantly
associated with delayed sputum smear conversion.
doi:10.1371/journal.pone.0091229.t003
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transmission, as well as decreased mortality associated with TB.
In conclusion, anemia at the initiation TB treatment is
significantly associated with delayed sputum smear conversion
among sputum positive TB patients with a dose-response effect.
The mechanisms mediating this relationship need to be deter-
mined in-order to institute effective interventions. Further studies
should seek to understand the mechanisms for anemia among TB
patients and assess the efficacy of treating anemia in a randomized
setting as a means to improve TB outcomes.
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